NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
Experienced life sciences executive Dr Ruben Herrendorff appointed as CEO Serial biotech entrepreneur Dr Ulf Grawunder appointed as Board member Targeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the current non-selective immunosuppression 30 November 2022, Basel, Switzerland – NXI Therapeutics[1], the specialist biotech developing next generation immunosuppressive drugs for autoimmune […]